Kythera lipoma drug doubles as chin-thinner, US results confirm
This article was originally published in Scrip
Executive Summary
Kythera Biopharmaceuticals has reported more promising Phase II results from a US study of its investigational product, the injectable adiopolytic agent, ATX-101 (Sodium Deoxycholate for Injection) for reduction of fat under the chin (submental fat). The company hopes the results will provide it entry into the lucrative aesthetic dermatology business. The company has also been pursuing ATX-101 in Phase II studies for the treatment of superficial lipomas.